Evidence map›Paper›PMID 31801720›Full record

ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2019

[Bioinformatic analysis of direct protein targets of aspirin against human breast cancer proliferation].

Xingmei Zhu, Jiani Yang, Enhu Zhang, Wei Qiao, Xuejun Li

Abstract read
In one paragraph

Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Xingmei ZhuDepartment of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang 712046, China.
Jiani YangDepartment of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang 712046, China.
Enhu ZhangDepartment of Pharmacology, Shaanxi University of Chinese Medicine, Xianyang 712046, China.
Wei QiaoDepartment of Gastroenterology, 521 Hospital of Norinco Group, Shaanxi, Xi'an, 710065, China.
Xuejun LiSchool of Basic Medicine, Peking University Health Science Center, Beijing, 100191, China.
Shaanxi University of Chinese Medicine · CNFirst Hospital of Xi'an · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the molecular mechanism underlying the inhibitory effects of aspirin against human breast cancer cell proliferation through bioinformatics analysis.

methodsDrug Bank 5.1.3 was searched to identify direct protein targets (DPTs) of aspirin, and the protein-protein interaction (PPI) network of the DPTs was constructed online using STRING and the signaling pathways involved were identified. The genetic alterations of 6 DPTs associated with human breast cancer was analyzed and visualized by cBio Portal and OncoPrint, respectively. The transcriptomic data of breast cancer and normal tissues were downloaded from TCGA database, and the overexpressed genes were analyzed by DECenter. The intersection between the genes associated with the DPTs obtained by STRING analysis and the differentially over-expressed genes in TCGA was determined to confirm the candidate DPTs as a potential target of aspirin, and GO functional enrichment analysis was performed using Gene Ontology. The potential targets of aspirin against the proliferation of human breast cancer cells were verified by Western blotting.

resultsEleven DPTs of aspirin were identified. KEGG pathway enrichment indicated that 6 genes (EDNRA, IKBKB, NFKB2, NFKBIA, PTGS2 and TP53) were associated with the occurrence and development of cancer. A total of 10 220 differentially expressed genes were identified from the TCGA database, and among them 4 genes (

conclusions

Indexed as

Computational BiologyAspirinBreast NeoplasmsCdc20 Proteinscdc25 PhosphatasesCell Cycle ProteinsCell ProliferationGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMicrotubule-Associated ProteinsPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsAspirinCDC20 protein, humanCdc20 ProteinsCDC25C protein, humancdc25 PhosphatasesCell Cycle ProteinsMicrotubule-Associated ProteinsPolo-Like Kinase 1Protein Serine-Threonine KinasesProto-Oncogene ProteinsTPX2 protein, humanaspirinbioinformaticscell cyclecell divisionhuman breast cancer

Identifiers

PMID31801720
PMCPMC6867953
OpenAlexW2998810165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.